CTMT212X2102: Phase I, Open-Label Study to Determine the Effect of Repeat Dosing of Trametinib on the Pharmacokinetics of a Combined Oral Contraceptive (Norethindrone plus Ethinyl Estradiol) in Female Patients with Solid Tumors

February 16, 2019
https://clinicaltrials.gov/ct2/results?id=NCT02705963
Cancer - Colon Rectal, Solid Tumors, Cancer - Gynecologic/ Ovarian
Principal Investigator: Ding Wang, MD
Gastrointestinal, Gastrointestinal Anus, Rectal, Rectal Colon, Solid tumors, Phase I, Open-Label, Female, Oral Contraceptive, Norethindrone, Ethinyl Estradiol, ovarian, ovarian cancer
Open